Opinion

Video

Role of Antibody-Drug Conjugates in NSCLC Treatment: Insights from EVOKE-02

Benjamin Levy, MD, leads discussion on the promising potential of antibody-drug conjugates (ADCs) in treating non-small cell lung cancer (NSCLC) with non-actionable mutations, while Helena A. Yu, MD, presents an overview of the EVOKE-02 study, emphasizing key efficacy and safety data that could significantly impact the current treatment landscape.

  1. Briefly discuss the potential role of ADCs in NSCLC with non-actionable mutations.
    1. What is the rationale for use of ADCs in this treatment space?
    2. What characteristics may allow ADCs to be more advantageous in this treatment space over other traditional chemotherapy and targeted agents?
    3. Which ADCs are most likely to have potential benefit here and why?
  2. Please review the rationale and study design for EVOKE-02 and discuss key efficacy and safety data and the implications these findings may have on the treatment landscape. (Garon, et al. J Clin Oncol, 2022; Cho, et al. WCLC 2023; Cappuzzo et al. WLC 2024. Efficacy results by histology from the EVOKE-2 study; ASCO 2024 Patel et al. SG + Pembro in 1L mNSCLC with PD-L1 ≥50%: Cohort A of EVOKE-02) 
    1. What do data demonstrateregarding the efficacy of SG + pembro in patients with NSCLC and how does response differ by PD-L1 expression?
    2. Other key takeaways? What implications could these findings have on clinical practice?
    3. Which patients stand to benefit the greatest from this treatment approach?
Related Videos
2 KOLs are featured in this program.
2 KOLs are featured in this program.
2 KOLs are featured in this series
2 KOLs are featured in this series
A panel of 5 experts on breast cancer
5 KOLs are featured in this peer exchange
A panel of 5 experts on breast cancer
5 KOLs are featured in this peer exchange
2 KOLs are featured in this series
3 KOLs are featured in this series.